{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:18:49Z","timestamp":1781713129061,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141117"],"award-info":[{"award-number":["82141117"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Capital's Funds for Health Improvement and Research","award":["2022\u20132\u20131023"],"award-info":[{"award-number":["2022\u20132\u20131023"]}]},{"name":"The Beijing Municipal Administration of Hospitals Incubating Program","award":["PX2020045"],"award-info":[{"award-number":["PX2020045"]}]},{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2021\u201316\u201319"],"award-info":[{"award-number":["320.6750.2021\u201316\u201319"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Fund for Distinguished Young Scholars of Beijing Cancer Hospital","award":["QNJJ2022012"],"award-info":[{"award-number":["QNJJ2022012"]}]},{"name":"Guangzhou Life oasis public service center Research and exchange program in the field of health","award":["1\u201335"],"award-info":[{"award-number":["1\u201335"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03387-7","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T12:02:56Z","timestamp":1707393776000},"page":"1664-1673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum\/etoposide: a focus on patients with brain metastasis"],"prefix":"10.1007","volume":"26","author":[{"given":"Hanxiao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2489-7791","authenticated-orcid":false,"given":"Minglei","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"3387_CR1","unstructured":"American Cancer Society Lung cancer survival rates: 5-year survival rates for lung cancer. https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/detection-diagnosis-staging\/survival-rates.html"},{"key":"3387_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/COC.0000000000000867","volume":"44","author":"R Rittberg","year":"2021","unstructured":"Rittberg R, Banerji S, Kim JO, Rathod S, Dawe DE. Treatment and prevention of brain metastases in small cell lung cancer. Am J Clin Oncol. 2021;44:629\u201338.","journal-title":"Am J Clin Oncol"},{"key":"3387_CR3","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1200\/JCO.2002.12.111","volume":"20","author":"S Sundstr\u00f8m","year":"2002","unstructured":"Sundstr\u00f8m S, Bremnes RM, Kaasa S, Aaseb\u00f8 U, Hatlevoll R, Dahle R, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years\u2019 follow-up. J Clin Oncol. 2002;20:4665\u201372.","journal-title":"J Clin Oncol"},{"key":"3387_CR4","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139.","journal-title":"N Engl J Med"},{"key":"3387_CR5","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929\u201339.","journal-title":"Lancet"},{"key":"3387_CR6","unstructured":"The Chinese Society of Clinical Oncology Clinical guidelines for the diagnosis and treatment of small-cell lung cancer"},{"key":"3387_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.21147\/j.issn.1000-9604.2022.04.04","volume":"34","author":"H Chen","year":"2022","unstructured":"Chen H, Ma X, Liu J, Yang Y, Fang Y, Wang L, et al. Clinical outcomes of atezolizumab in combination with etoposide\/platinum for treatment of extensive-stage small-cell lung cancer: a real-world, multicenter, retrospective, controlled study in China. Chin J Cancer Res. 2022;34:353\u201364.","journal-title":"Chin J Cancer Res"},{"key":"3387_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619\u201330.","journal-title":"J Clin Oncol"},{"key":"3387_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51\u201365.","journal-title":"Lancet Oncol"},{"key":"3387_CR10","volume":"2","author":"AA Elegbede","year":"2021","unstructured":"Elegbede AA, Gibson AJ, Fung AS, Cheung WY, Dean ML, Bebb DG, et al. A real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with extensive-stage SCLC in Canada. JTO Clin Res Rep. 2021;2: 100249.","journal-title":"JTO Clin Res Rep"},{"key":"3387_CR11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00262-021-03052-w","volume":"71","author":"S Lee","year":"2022","unstructured":"Lee S, Shim HS, Ahn BC, Lim SM, Kim HR, Cho BC, et al. Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. Cancer Immunol Immunother. 2022;71:1093\u2013101.","journal-title":"Cancer Immunol Immunother"},{"key":"3387_CR12","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s11864-022-00989-7","volume":"23","author":"B Schlick","year":"2022","unstructured":"Schlick B, Shields MD, Marin-Acevedo JA, Patel I, Pellini B. Immune checkpoint inhibitors and chemoradiation for limited-stage small cell lung cancer. Curr Treat Options Oncol. 2022;23:1104\u201320.","journal-title":"Curr Treat Options Oncol"},{"key":"3387_CR13","unstructured":"NCCN Guidelines Version 3.2023. https:\/\/www.nccn.org\/guidelines\/recently-published-guidelines"},{"key":"3387_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.03.002","volume":"179","author":"A Sun","year":"2023","unstructured":"Sun A, Abdulkarim B, Blais N, Greenland J, Louie AV, Melosky B, et al. Use of radiation therapy among patients with extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations. Lung Cancer. 2023;179: 107166.","journal-title":"Lung Cancer"},{"key":"3387_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12885-023-10784-8","volume":"23","author":"L Li","year":"2023","unstructured":"Li L, Yang D, Min Y, Liao A, Zhao J, Jiang L, et al. First-line atezolizumab\/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer. BMC Cancer. 2023;23:318.","journal-title":"BMC Cancer"},{"key":"3387_CR16","doi-asserted-by":"publisher","first-page":"1175960","DOI":"10.3389\/fimmu.2023.1175960","volume":"14","author":"C Liu","year":"2023","unstructured":"Liu C, Zeng L, Deng C, Jiang W, Wang Y, Zhou Y, et al. Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer. Front Immunol. 2023;14:1175960.","journal-title":"Front Immunol"},{"key":"3387_CR17","doi-asserted-by":"crossref","unstructured":"Zhou L, Sun J, Xie C, Gong Y, Huang M, Yuan Z et al. Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC: interim analysis of Phase II MATCH trial. J Clin Oncol. 2022;40:e20611-e","DOI":"10.1200\/JCO.2022.40.16_suppl.e20611"},{"key":"3387_CR18","doi-asserted-by":"publisher","first-page":"S1165","DOI":"10.1016\/j.annonc.2021.08.236","volume":"32","author":"JM Galuba","year":"2021","unstructured":"Galuba JM, St\u00f6ver I, Koziorowski A, B\u00f6l\u00fckbas S, Nilius G, Christoph DC. 1652P Safety of simultaneously performed radiotherapy in patients with small cell lung cancer undergoing atezolizumab treatment. Ann Oncol. 2021;32:S1165.","journal-title":"Ann Oncol"},{"key":"3387_CR19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1186\/s12885-022-10074-9","volume":"22","author":"F Bozorgmehr","year":"2022","unstructured":"Bozorgmehr F, Christopoulos P, Chung I, Cvetkovic J, Fei\u00dft M, Krisam J, et al. Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease \u2013 a randomized, open-label, multicenter phase II trial. BMC Cancer. 2022;22:1011.","journal-title":"BMC Cancer"},{"key":"3387_CR20","doi-asserted-by":"publisher","first-page":"S1060","DOI":"10.1016\/j.annonc.2023.09.1219","volume":"34","author":"F Bozorgmehr","year":"2023","unstructured":"Bozorgmehr F, Weykamp F, Overbeck TR, Maguire N, Buchmeier EL, Hammer-Hellmig M, et al. 1988MO recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data. Ann Oncol. 2023;34:S1060.","journal-title":"Ann Oncol"},{"key":"3387_CR21","doi-asserted-by":"publisher","first-page":"S706","DOI":"10.1016\/j.jtho.2023.09.1362","volume":"18","author":"K Yamamoto","year":"2023","unstructured":"Yamamoto K, Hirano K, Ninomaru T, Okada H, Shimada T, Hata A. EP13.07-02 is concept of continuous immunotherapy beyond progression effective in small cell lung cancer? J Thorac Oncol. 2023;18:S706.","journal-title":"J Thorac Oncol"},{"key":"3387_CR22","doi-asserted-by":"publisher","first-page":"967559","DOI":"10.3389\/fphar.2022.967559","volume":"13","author":"L Li","year":"2022","unstructured":"Li L, Liu T, Liu Q, Mu S, Tao H, Yang X, et al. Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer. Front Pharmacol. 2022;13:967559.","journal-title":"Front Pharmacol"},{"key":"3387_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11060-022-04111-7","volume":"159","author":"J Ma","year":"2022","unstructured":"Ma J, Tian Y, Hao S, Zheng L, Hu W, Zhai X, et al. Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis. J Neurooncol. 2022;159:685\u201393.","journal-title":"J Neurooncol"},{"key":"3387_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"3387_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337\u201341.","journal-title":"Nature"},{"key":"3387_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12885-019-5741-y","volume":"19","author":"MTJ van Bussel","year":"2019","unstructured":"van Bussel MTJ, Beijnen JH, Brandsma D. Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. BMC Cancer. 2019;19:519.","journal-title":"BMC Cancer"},{"key":"3387_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13014-020-01644-x","volume":"15","author":"ES Kowalski","year":"2020","unstructured":"Kowalski ES, Remick JS, Sun K, Alexander GS, Khairnar R, Morse E, et al. Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases. Radiat Oncol. 2020;15:245.","journal-title":"Radiat Oncol"},{"key":"3387_CR28","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/neuonc\/noab129","volume":"23","author":"S Scoccianti","year":"2021","unstructured":"Scoccianti S, Olmetto E, Pinzi V, Osti MF, Di Franco R, Caini S, et al. Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO. Neuro Oncol. 2021;23:1750\u201364.","journal-title":"Neuro Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03387-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03387-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03387-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T05:11:27Z","timestamp":1718341887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03387-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["3387"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03387-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics Committee of Beijing Cancer Hospital (NO. 2021YJZ33-GZ01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Informed consent was waived by the Ethics Committee because of the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}